CLIRF yields 1000000.00% · JNJ yields 2.13%● Live data
📍 CLIRF pulled ahead of the other in Year 1
Combined, CLIRF + JNJ cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of CLIRF + JNJ for your $10,000?
Clearford Water Systems Inc., a water management company, provides unified water infrastructure solutions in Canada, the United States, India, South America, and internationally. It operates in three segments: Waterworks, Water & Wastewater Infrastructure Delivery, and UV Pure Disinfection. The company offers Clearford One, a three-stage solution for wastewater servicing; ClearDigest, an on-site pre-treatment stage that removes solids at the source; ClearConvey, a network of small bore sewer pipes that carries liquids without any infiltration to an optimized facility for final treatment; and ClearRecover, a treatment facility. It also provides Clearford M-brane, a lifecycle solution for managed and decentralized water treatment; Clearford UV, which offers potable, wastewater, reuse, and rainwater disinfection systems; and Clearford Pay-for-Performance project financing program solutions. In addition, the company designs, manufactures, and sells ultraviolet purification systems using its patented Crossfire technology into the potable water, wastewater, reuse, and rainwater harvesting markets. Further, it provides water supply and wastewater treatment systems for small communities, as well as manufactures and supplies packaged treatment solutions, including containerized membrane plants for advanced water treatment. The company was formerly known as Clearford Industries Inc. and changed its name to Clearford Water Systems Inc. in June 2014. Clearford Water Systems Inc. is headquartered in Ottawa, Canada.
Full CLIRF Calculator →Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.
Full JNJ Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.